2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Promyelocytic, Acute
2
Leukemia, Myeloid, Acute
2
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Pancreatic Neoplasms
1
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Gemcitabine
13
pembrolizumab
9
Specimen Handling
9
enfortumab vedotin
8
Cisplatin
8
Magnetic Resonance Spectroscopy
7
avelumab
5
Carboplatin
5
vinflunine
4
Nivolumab
4
atezolizumab
3
Immunoglobulin G
3
Disulfides
3
Biopsy
3
eribulin
2
cabozantinib
2
Standard of Care
2
Ramucirumab
2
Radiotherapy
2
Platinum
2
Nephroureterectomy
2
Ipilimumab
2
Doxorubicin
2
Docetaxel
2
CTLA-4 Antigen
2
Bortezomib
2
1,2-diaminocyclohexaneplatinum II citrate
2
vandetanib
1
tremelimumab
1
tocilizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ureteral Neoplasms
×
tamibarotene
×
Clear all
NCT06983210
2025-08-14
GRAPE
Nagoya University
Phase 2
Recruiting
43 enrolled